Everen Group Appoints Robert Foskey as President & CEO
6.8.2024 22:10:00 EEST | Business Wire | Press release
The Everen Group, a group of leading energy insurance companies, is pleased to announce the appointment of Robert Foskey as the new President & Chief Executive Officer, effective August 5, 2024. Mr. Foskey brings a wealth of experience and a proven track record of success with the Everen Group and is set to lead the company into its next phase of growth and innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806098310/en/
Robert Foskey Appointed President & CEO of Everen Group (Photo: Business Wire)
Over the past 17 years with the Everen Group, Mr. Foskey has demonstrated exceptional leadership and strategic vision, in his capacity as the Group Chief Actuary for 15 years and most recently as the Chief Operating Officer of Everen Limited. He has overseen key operational improvements and driven significant growth. Mr. Foskey has a deep understanding of the Group’s mission and values, making him the ideal choice for the role of CEO.
Mr. Foskey’s selection is the culmination of a robust, year-long leadership succession search process led by the Board. “We are extremely pleased to appoint Rob as Group CEO,” said John Weisner, Chair of the Board of Everen Limited. “His contributions as Chief Actuary and COO have been invaluable, and the Board is confident he will continue to propel the Everen Group forward with the same dedication and inspiration. The Board would also like to thank Bertil Olsson for his contributions to the Everen Group as CEO over the past nine years.”
John Talarico, Chair of the Board of Everen Specialty Ltd., added, “The Board unanimously agree that Rob is the ideal leader for the Everen Group. His in-depth knowledge of our operations and commitment to our organization will ensure a seamless transition and continued success.”
Commenting on his appointment, Mr. Foskey said, “I am honored and excited to take on the role of Group CEO. It has been a privilege to be a part of the Everen Group and to lead Everen Limited as COO. I want to thank the Board for its confidence as I step into this role. I look forward to working with our talented leadership team and employees as we continue to innovate and deliver consistent value to our shareholders and customers and advance the Group’s position as leaders in the global insurance industry. I am committed to fulfilling our mission and values and enhancing our culture through teamwork, collaboration and transparency.”
About Everen Group:
The Everen Group includes two distinct operating companies providing complementary products: Everen and Everen Specialty. Everen is the largest energy insurance mutual company in the world, operating for over 50 years and acting as a pure mutual owned by its member shareholders. Its underwriting is 100% supported by its own balance sheet with no third party capital and it offers up to $450 million of per occurrence limits. Everen Specialty is an industry owned commercial (re)insurer offering property and casualty insurance and reinsurance for members and non-members. Everen Specialty also have a subsidiary, OCIL Specialty, Ltd (OSL), writing U.S. surplus lines business through OSL Insurance Services (OISI), a managing general agent based in Houston, Texas.
For further information about the companies, please visit Everen.bm and EverenSpecialty.bm.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806098310/en/
Contacts
For inquiries regarding this press release, please contact Karyn Peixoto, VP,
Human Resources & Administration on hr@everengroup.bm
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom